Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/131737
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Limited utility of plasma elafin as a biomarker for skin graft-versus-host disease following allogeneic stem cell transplantation |
Author: | George, L. Mahabal, G. Mohanan, E. Balasubramanian, P. Peter, D. Pulimood, S. Lakshmi, K. Jeyaseelan, L. Abraham, A. Srivastava, A. Mathews, V. George, B. |
Citation: | Clinical and Experimental Dermatology, 2021; 46(8):1482-1487 |
Publisher: | Wiley |
Issue Date: | 2021 |
ISSN: | 0307-6938 1365-2230 |
Statement of Responsibility: | L. George, G. Mahabal, E. Mohanan, P. Balasubramanian, D. Peter, S. Pulimood ... et al. |
Abstract: | Background: Acute cutaneous graft-versus-host disease (acGVHD) following haematopoietic stem cell transplant (HSCT) is common but difficult to distinguish from other causes of rash. Plasma elafin has been proposed as a diagnostic and prognostic biomarker of skin GVHD. Aim: To evaluate the role of plasma elafin as a biomarker in acGVHD in an Indian population. Methods: Plasma elafin was evaluated in a prospective study of HSCT recipients, conducted over 2 years, taking measurements at baseline and at onset of skin rash after HSCT. Patients were categorized into those with GVHD rash, those with non-GVHD rash and those with no rash and the three groups were compared. Results: Two hundred and sixty-one patients with a median age of 16 years (range 1–61 years) and a male predominance (175 : 86 M/F) underwent HSCT during the study period: 56 patients in the GVHD group, 49 in the non-GVHD group and 156 in the no-rash group. The median baseline elafin was similar in all three groups. At the onset of rash, median elafin level was similar between GVHD and non-GVHD rash (34 549 vs. 32 077 pg/mL; P = 0.58) and between GVHD and no rash (34 549 vs. 26 197 pg/mL; P = 0.08). A rise in elafin from baseline was significantly different between GVHD and no rash (P < 0.001) but not between GVHD and non-GVHD rash (P = 0.44). Conclusion: The utility of plasma elafin as a biomarker of skin GVHD is very limited. Plasma elafin, although elevated in cutaneous GVHD, is not helpful in distinguishing between GVHD rash and other causes of rash following HSCT. |
Keywords: | Humans Exanthema Graft vs Host Disease Diagnosis, Differential Hematopoietic Stem Cell Transplantation Adolescent Adult Middle Aged Child Child, Preschool Infant Female Male Elafin Young Adult Biomarkers |
Description: | First published: 03 June 2021 |
Rights: | © 2021 British Association of Dermatologist |
DOI: | 10.1111/ced.14785 |
Published version: | http://dx.doi.org/10.1111/ced.14785 |
Appears in Collections: | Aurora harvest 4 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.